Last 1,142 GBp
Change Today +11.00 / 0.97%
Volume 7.5M
SN/ On Other Exchanges
Symbol
Exchange
London
Frankfurt
Frankfurt
As of 11:35 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

smith & nephew plc (SN/) Snapshot

Open
1,120 GBp
Previous Close
1,131 GBp
Day High
1,148 GBp
Day Low
1,113 GBp
52 Week High
03/3/15 - 1,216 GBp
52 Week Low
04/16/14 - 858.50 GBp
Market Cap
10.2B
Average Volume 10 Days
3.4M
EPS TTM
0.56 GBp
Shares Outstanding
895.6M
EX-Date
04/16/15
P/E TM
31.1x
Dividend
0.32 GBp
Dividend Yield
1.65%
Current Stock Chart for SMITH & NEPHEW PLC (SN/)

Related News

No related news articles were found.

smith & nephew plc (SN/) Related Businessweek News

No Related Businessweek News Found

smith & nephew plc (SN/) Details

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The company’s Advanced Surgical Devices segment offers orthopaedic reconstruction implants for hip, knee, and shoulder joints; and ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. It also provides sports medicine products, which offer surgeons an array of instruments, technologies, and implants to perform minimally invasive surgery of the joints, including knee, hip, and shoulder repair; and trauma and extremities products consisting of internal and external devices and other products, including shoulder fixation and orthobiological materials used in the stabilization of fractures and deformity correction procedures. In addition, this segment provides arthroscopy enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, as well as offers radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissues to healthcare providers. The company’s Advanced Wound Management segment offers a range of initial wound bed preparation and full wound closure products. Its products are targeted at chronic wounds associated with the older population, such as pressure sores and venous leg ulcers; and products for the treatment of wounds, such as burns and invasive surgery. Smith & Nephew plc primarily serves medical and surgical treatments and service providers. The company was founded in 1856 and is headquartered in London, the United Kingdom.

14,000 Employees
Last Reported Date: 02/5/15
Founded in 1856

smith & nephew plc (SN/) Top Compensated Officers

Chief Executive Officer, Director, Chairman o...
Total Annual Compensation: $4.2M
Chief Financial Officer, Director and Member ...
Total Annual Compensation: $2.0M
Compensation as of Fiscal Year 2013.

smith & nephew plc (SN/) Key Developments

Smith & Nephew Falls On Bid Rumours

Smith & Nephew plc (LSE:SN.), which only a day earlier had been puffed up by bid speculation, suffered the heaviest fall in the FTSE 100 after takeover hopes began to evaporate. Although it was Johnson & Johnson (NYSE:JNJ) that was rumored to be weighing an approach for the FTSE 100 company, traders have long considered a bid from Stryker Corporation (NYSE:SYK) as more likely.Takeover Panel rules prohibited the company from making a bid for six months but those restrictions lifted last November and ever since there has been growing speculation that Stryker would revive its interest.

Smith & Nephew plc Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

Smith & Nephew plc announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of $1,249 million compared with $1,175 million for the same period a year ago. Operating profit was $226 million compared with $235 million for the same period a year ago. Profit before tax was $212 million compared with $232 million for the same period a year ago. Attributable profit was $160 million or 17.8 cents per diluted share compared with $162 million or 18.0 cents per diluted share for the same period a year ago. Net cash flow from operating activities was $302 million compared with $321 million for the same period a year ago. Capital expenditures was $118 million compared with $125 million for the same period a year ago. For the full year, the company reported revenues of $4,617 million compared with $4,351 million for the same period a year ago. Operating profit was $749 million compared with $810 million for the same period a year ago. Profit before tax was $714 million compared with $802 million for the same period a year ago. Attributable profit was $501 million or 55.7 cents per diluted share compared with $556 million or 61.4 cents per diluted share for the same period a year ago. Net cash flow from operating activities was $683 million compared with $867 million for the same period a year ago. Capital expenditures was $375 million compared with $340 million compared with for the same period a year ago. Net debt was $1,613 million compared with $253 million for the same period a year ago. The company provided earnings guidance for the full year of 2015. The company expects the Group to deliver higher underlying revenue growth in 2015 than in 2014. The company expects to deliver a further improvement in trading profit margin in 2015. Additionally, the company expects the effective corporate tax rate to reduce to slightly above 27% in 2015, absent any changes to tax legislation. This is incremental to the 220bps reduction achieved in the last two years.

Smith & Nephew plc Recommends Final Dividend for the Year Ended December 31, 2014, Payable on May 6, 2015

The Board of Smith & Nephew plc recommend a final dividend of 18.6 cents per share (37.2 cents per ADS) for the year ended December 31, 2014. This, together with interim dividend of 11.0 cents per share (22.0 cents per ADS), will give a full year distribution of 29.6 cents per share (59.2 cents per ADS), up 8% year-on-year. The dividend for 2014 will be payable, subject to shareholder approval, on 6 May 2015 to shareholders whose names appear on the register at the close of business on 17 April 2015. The sterling equivalent per ordinary share will be set following the record date. The ex-dividend date is 16 April 2015 and the final day for currency and dividend reinvestment plan elections is 17 April 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SN/:LN 1,142.00 GBp +11.00

SN/ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $167.75 USD +0.57
Edwards Lifesciences Corp $135.75 USD +1.17
Olympus Corp ¥4,300 JPY -5.00
St Jude Medical Inc $67.12 USD -0.48
Zimmer Holdings Inc $118.81 USD -0.46
View Industry Companies
 

Industry Analysis

SN/

Industry Average

Valuation SN/ Industry Range
Price/Earnings 31.2x
Price/Sales 3.4x
Price/Book 3.8x
Price/Cash Flow 31.1x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SMITH & NEPHEW PLC, please visit www.smith-nephew.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.